Donepezil Hydrochloride
Product Images NDC 46708-093

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 46708-093). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg-30 Tablets In Hdpe Bottle Pack (Donepezil 10mg)

Donepezil Hydrochloride Tablets USP 10 mg film-coated tablet label from Alembic Pharmaceuticals Limited. The label states the dosage strength as 10 mg per tablet, a total of 30 tablets per container, and includes storage instructions of 20 to 25°C. It also displays the NDC 46708-093-30, barcode, and manufacturer details located in Gujarat, India.*

FDA Label Image

5 mg-30 Tablets In Hdpe Bottle Pack (Donepezil 5mg)

Donepezil Hydrochloride Tablets, USP 5 mg label showing the NDC number 46708-092-30. The label states the product contains 5 mg donepezil hydrochloride per film-coated tablet, with 30 tablets per container. It is manufactured by Alembic Pharmaceuticals Limited. The label includes storage instructions, a barcode, and space for lot and expiration dates.*

FDA Label Image

Figure 1 (Donepezil Figure1)

A line chart illustrating the time-course change from baseline in ADAS-cog score over 24 weeks of drug treatment. It compares three groups: Donepezil hydrochloride 10 mg/day, Donepezil hydrochloride 5 mg/day, and placebo. The y-axis shows mean change from baseline with standard error bars; the x-axis indicates weeks of treatment from 0 to 24. The chart shows clinical improvement direction upward and clinical decline downward.*

FDA Label Image

Figure 10 (Donepezil Figure10)

A cumulative percentage line graph depicting the change from baseline in ADCS-ADL scores over 6 months for patients treated with Donepezil hydrochloride 10 mg/day compared to a placebo group. The x-axis shows change from baseline with negative and positive values, while the y-axis represents the cumulative percentage of patients. Two lines represent treatment and placebo groups.*

FDA Label Image

Figure 2 (Donepezil Figure2)

A cumulative percentage graph showing patients' changes from baseline in ADAS-cog scores over 24 weeks for placebo, Donepezil hydrochloride 5 mg, and Donepezil hydrochloride 10 mg treatment groups. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. The graph includes a table summarizing the percentages of patients with changes at 7 points, 4 points, and no change.*

FDA Label Image

Figure 3 (Donepezil Figure3)

A bar chart comparing the percentage distribution of patients' CIBIC-plus scores at Week 24 for Donepezil hydrochloride 10 mg/day, Donepezil hydrochloride 5 mg/day, and placebo groups. The ratings range from Markedly Improved to Markedly Worse, showing frequencies of patient outcomes across these categories.*

FDA Label Image

Figure 4 (Donepezil Figure4)

A line graph showing the change from baseline in ADAS-cog scores over 15 weeks for patients treated with Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The graph depicts clinical improvement and decline trends across the study period, with error bars indicating standard error at multiple time points.*

FDA Label Image

Figure 5 (Donepezil Figure5)

A cumulative percentage curve chart showing patients with specified changes from baseline ADAS-cog scores by treatment group: placebo, donepezil hydrochloride 5 mg, and donepezil hydrochloride 10 mg. The chart tracks cognitive score changes from -15 to +10, with annotations at 7 points, 4 points, and no change, accompanied by a table summarizing percentage improvements in each group.*

FDA Label Image

Figure 6 (Donepezil Figure6)

A bar chart showing the frequency distribution of CIBIC-plus scores at Week 12 for patients taking Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis lists categories from Markedly Improved to Markedly Worse, and the y-axis shows the percentage of patients. The chart visually compares patient responses across three groups.*

FDA Label Image

Figure 7 (Donepezil Figure7)

A line graph showing the time course of change from baseline in SIB score over 6 months of drug treatment. It compares Donepezil hydrochloride 10 mg/day and placebo groups, with Donepezil showing clinical improvement while placebo shows clinical decline over the period.*

FDA Label Image

Figure 8 (Donepezil Figure8)

A cumulative percentage curve graph showing patients completing 6 months of double-blind treatment with donepezil hydrochloride 10 mg/day versus placebo. The horizontal axis represents SIB (Severe Impairment Battery) change from baseline, and the vertical axis shows the cumulative percentage of patients, highlighting the treatment effect over the range of SIB scores.*

FDA Label Image

Figure 9 (Donepezil Figure9)

A line graph depicting the time course of change from baseline in ADCS-ADL-Severe scores over 6 months of drug treatment. It compares donepezil hydrochloride 10 mg/day and placebo groups, showing mean changes with standard error bars at 0, 3, and 6 months. The y-axis ranges from clinical improvement to clinical decline.*

FDA Label Image

Structure (Donepezil Structure)

Chemical structure diagram of donepezil hydrochloride, showing its molecular framework including aromatic rings, piperidine ring, methoxy groups, and hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.